Baird on Axsome Therapeutics (AXSM): 'Incrementally positive on regulatory updates'

Axsome Therapeutics (AXSM) PT Raised to $230 at B.Riley

B.Riley analyst Madison El-Saadi raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $230.00 (from $184.00) while maintaining a Buy rating.

Leerink on Axsome Therapeutics (AXSM): 'This is very positive news'

Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $150.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst comments "This is very positive news for Axsome, as Alzheimer's disease agitation (AD-A) is a key additional indication to drive... More

Axsome Therapeutics (AXSM) PT Raised to $217 at Mizuho

Mizuho analyst Graig Suvannavejh raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $217.00 (from $202.00) while maintaining a Outperform rating.

The analyst comments "This morning, AXSM announced two pieces of positive regulatory news: (1) at long last, FDA acceptance of the sNDA for AXS-05... More

Axsome Therapeutics (AXSM) PT Raised to $220 at Oppenheimer

(Updated - December 31, 2025 12:42 PM EST)

Oppenheimer analyst Jay Olson raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $220.00 (from $190.00) while maintaining a Outperform rating.

The analyst commented: "We see FDA's acceptance of the sNDA for Auvelity in ADA with priority review as... More

Morgan Stanley on Axsome Therapeutics (AXSM)

Morgan Stanley analyst Sean Laaman reiterated an Overweight rating and $196.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst comments "FDA's acceptance of AXSM's sNDA for AXS-05 in ADA removes a major overhang on the stock, validates the pipeline and management's... More

Axsome Therapeutics (AXSM) PT Raised to $169 at Needham

Needham analyst Ami Fadia raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $169.00 (from $154.00) while maintaining a Buy rating.

Truist on Axsome Therapeutics (AXSM): 'We fully expect ADA to be a significantly larger opportunity for AXS-05'

Truist Securities analyst Joon Lee reiterated a Buy rating and $200.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst comments "This AM, AXSM disclosed acceptance of AXS-05 sNDA for ADA with priority review (upside to our base case). PDUFA is set... More

TD Cowen on Axsome Therapeutics (AXSM): 'the sNDA acceptance should be well received by investors'

TD Cowen analyst Joseph Thome reiterated a Buy rating and $190.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst comments "Axsome announced that the FDA accepted the Auvelity sNDA for ADA with priority review and assigned an April 30th PDUFA date. Given... More

Axsome gets FDA priority review for Alzheimer's agitation drug

Axsome Therapeutics Inc. (NASDAQ: AXSM) announced the U.S. Food and Drug Administration has accepted its supplemental new drug application for AXS-05 to treat Alzheimer's disease agitation and granted priority review designation. The FDA set a target action date of April 30, 2026.

AXS-05 combines dextromethorphan and bupropion in a proprietary... More

Axsome receives FDA feedback supporting AXS-12 narcolepsy drug filing

Axsome Therapeutics Inc. (NASDAQ: AXSM) received formal pre-New Drug Application meeting minutes from the U.S. Food and Drug Administration supporting an NDA submission for AXS-12 in narcolepsy treatment, according to a company statement.

The FDA indicated that Axsome's regulatory data package would be sufficient for submitting an NDA for AXS-12 to treat... More